Yitian Zhou

Yitian Zhou

Postdoctoral Researcher
Visiting address: Solnavägen 9, Biomedicum, 17165 Solna
Postal address: C3 Fysiologi och farmakologi, C3 FyFa Individanpassad medicin och läkemedelsutveckling, 171 77 Stockholm
Part of:

About me

  • Affiliation:
    LabMed https://ki.se/en/labmed/department-of-laboratory-medicine
    CBB https://ki.se/en/research/centre-for-bioinformatics-and-biostatistics-cbb
    *Publications*
    Siamoglou S, Koromina M, Hishinuma E, Yamazaki S, Tsermpini E, Kordou Z,
    Fukunaga K, Chantratita W, *Zhou Y*, Lauschke VM, Mushiroda T, Hiratsuka M,
    Patrinos GP. Identification and functional validation of novel
    pharmacogenomic variants using a next-generation sequencing-based approach
    for clinical pharmacogenomics./Pharmacological Research/. 2022
    Feb
  • 176:106087.
    Yang M, Johnsson P, Bräutigam L, Yang XR, Thrane K, Gao J, Tobin NP, *Zhou
    Y, *et al. Novel loss-of-function variant in DENND5A impedes melanosomal
    cargo transport and predisposes to familial cutaneous melanoma. /Genetics in
    Medicine/. 2022 Jan
  • 24(1):157-169.
    Genvigir FD Vecchia, Hernandez CD, Hirata TDC, *Zhou Y*, Lauschke VM, Hirata
    MH, Hirata RDC. Pharmacogenomics of Antihypertensive Drugs in Brazil: recent
    progress and clinical implications. /Endocrine, Metabolic &
  • Immune Disorders
    Drug Targets/. 2021 Dec 22.
    *Zhou Y*, Lauschke VM. Population pharmacogenomics: an update on
    ethnogeographic differences and opportunities for precision public health.
    /Human Genetics./ 2021 Oct 15.
    *Zhou Y*, Arribas G. H., Turku A., Lauschke VM et al. Rare genetic
    variability in human drugtarget genes modulates drug response and can guide
    precision medicine. /Science Advances/. 2021 Sep 3
  • 7(36)
    Dagli-Hernandez C., *Zhou Y*, Lauschke VM, et al. Pharmacogenomics of
    statins: lipid response and other outcomes in Brazilian cohorts.
    /Pharmacological Reports/. 2021.
    Hirata T. D. C., Dagli-Hernandez, C., Genvigir, F. D. V., Lauschke VM, *Zhou
    Y*, et al. Cardiovascular Pharmacogenomics: An Update on Clinical Studies of
    Antithrombotic Drugs in Brazilian Patients. /Molecular Diagnosis &
  • Therapy/.
    2021.
    *Zhou Y*, Lauschke VM. Computational tools to assess the functional
    consequences of rare and noncoding pharmacogenetic variability. /Clinical
    Pharmacology &
  • Therapeutics/. 2021
  • 17.
    Russell LE, *Zhou Y*, Almousa AA, Sodhi JK, Nwabufo CK, Lauschke VM.
    Pharmacogenomics in the era of next generation sequencing - from byte to
    bedside. /Drug Metabolism Reviews/. 2021
  • 17:1-26.
    Pernaute-Lau L, Adegnika AA, *Zhou Y*, Zinsou JF, et al. Pharmacogene
    sequencing of a Gabonese population with severe Plasmodium falciparum malaria
    reveals multiple novel variants with putative relevance for antimalarial
    treatment. /Antimicrobial Agents and Chemotherapy/. 2021
  • 19:AAC.00275-21.
    Wang T, *Zhou Y*, Cao G. Pharmacogenetics of tamoxifen therapy in Asian
    populations: from genetic polymorphism to clinical outcomes. /European
    Journal of Clinical Pharmacology/. 2021
  • 1-17
    Xiao Q, *Zhou Y*, Lauschke VM. Impact of variants in ATP-binding cassette
    transporters on breast cancer treatment. /Pharmacogenomics/. 2021
  • 21 (18),
    1299-1310
    *Zhou Y*, Hernandez C D, Lauschke VM. Population-scale predictions of DPD and
    TPMT phenotypes using a quantitative pharmacogene-specific ensemble
    classifier. /British Journal of Cancer/. 2020
    *Zhou Y*, Krebs K, Milani L, Lauschke VM. Global frequencies of clinically
    important HLA alleles and their implications for the cost‐effectiveness of
    preemptive pharmacogenetic testing. /Clinical Pharmacology &
  • Therapeutics/.
    2020
    Xiao Q, *Zhou Y*, Winter S, Büttner F, Schaeffeler E, Schwab M, et al.
    Germline variant burden in multidrug resistance transporters is a
    therapy‐specific predictor of survival in breast cancer patients.
    /International Journal of Cancer/. 2020
  • 146 (9), 2475-2487
    Xiao Q, *Zhou Y*, Lauschke VM. Ethnogeographic and inter-individual
    variability of human ABC transporters. /Human Genetics/. 2020
  • 1–24.
    Russell LE, *Zhou Y*, Lauschke VM, Kim RB. In Vitro Functional
    Characterization and in Silico Prediction of Rare Genetic Variation in the
    Bile Acid and Drug Transporter, Na+-Taurocholate Cotransporting Polypeptide
    (NTCP, SLC10A1). /Molecular Pharmaceutics/. 2020 Feb 26
  • 17(4):1170–81.
    *Zhou Y*, Lauschke VM. Pharmacogenomic network analysis of the gene-drug
    interaction landscape underlying drug disposition. /Computational and
    Structural Biotechnology Journal/. 2020
  • 18:52–8.
    Lauschke VM, Nordling Å, *Zhou Y*, Fontalva S, Barragan I, Ingelman-Sundberg
    M. CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular
    carcinoma. /Pharmacogenomics/. 2019
  • 20(15):1085–92.
    *Zhou Y*, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM. An optimized
    prediction framework to assess the functional impact of pharmacogenetic
    variants. /The pharmacogenomics journal/. 2018 Sep 12
  • 28(Suppl 3):1.
    Lauschke VM, *Zhou Y*, Ingelman-Sundberg M. Novel genetic and epigenetic
    factors of importance for inter-individual differences in drug disposition,
    response and toxicity. /Pharmacology &
  • therapeutics/. 2019 May
    1
  • 197:122–52.
    *Zhou Y*, Shen J, Lauschke VM. Comprehensive evaluation of current
    organotypic and microphysiological liver models for prediction of
    drug-induced liver injury. /Frontiers in pharmacology./ 2019
  • 10:1093.
    *Zhou Y*, Fujikura K, Mkrtchian S, Lauschke VM. Computational Methods for the
    Pharmacogenetic Interpretation of Next Generation Sequencing Data. /Frontiers
    in pharmacology/. 2018 Dec 4
  • 9:248.
    Ingelman-Sundberg M, Mkrtchian S, *Zhou Y*, Lauschke VM. Integrating rare
    genetic variants into pharmacogenetic drug response predictions. /Human
    Genomics/. 2018 Dec 1
  • 12(1):26.
    *Zhou Y*, Mägi R, Milani L, Lauschke VM. Global genetic diversity of human
    apolipoproteins and effects on cardiovascular disease risk. /Journal of lipid
    research/. 2018 Oct
  • 59(10):1987–2000.
    *Zhou Y*, Lauschke VM. Comprehensive overview of the pharmacogenetic
    diversity in Ashkenazi Jews. /Journal of Medical Genetics/. 2018 Sep
    1
  • 55(9):617–27.
    Vorrink SU, *Zhou Y*, Ingelman-Sundberg M, Lauschke VM. Prediction of
    drug-induced hepatotoxicity using long-term stable primary hepatic 3D
    spheroid cultures in chemically defined conditions. /Toxicological Sciences/.
    2018
  • 163(2):655–65.
    *Zhou Y*, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of
    cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing
    projects. /Clinical Pharmacology &
  • Therapeutics/. 2017
  • 102(4):688–700.
    *Zhou Y*, Zhou P, Xin Y, Wang J, Zhu Z, Hu J, et al. Trend of telomerase
    activity change during human iPSC self-renewal and differentiation revealed
    by a quartz crystal microbalance based assay. /Scientific reports/.
    2014
  • 4:6978.
    Lv B, *Zhou Y*, Cha W, Wu Y, Hu J, Li L, et al. Molecular composition,
    grafting density and film area affect the swelling-induced Au–S bond
    breakage. /ACS applied materials &
  • interfaces/. 2014
  • 6(11):8313–9.
    2017-2021, Karolinska Institutet, PhD in Pharmacogenetics
    2015-2017, Karolinska Institutet, Master of Medical Science in Toxicology
    2008-2012, China Pharmaceutical University, Bachelor of Science in Pharmacy

Articles

All other publications

Employments

  • Postdoctoral Researcher, Department of Physiology and Pharmacology, Karolinska Institutet, 2023-2025

Degrees and Education

  • Degree Of Doctor Of Philosophy, Department of Physiology and Pharmacology, Karolinska Institutet, 2021
  • Degree Of Master Of Medical Science 120 Credits, Karolinska Institutet, 2017

News from KI

Events from KI